NRx Pharmaceuticals, Inc.

With Spravato (esketamine) showing signs of solid growth during its fifth year on the market in 2024, Johnson & Johnson got another sign of confidence for the treatment-resistant depression drug o

The failure of NRx Pharmaceuticals, Inc. ’s NRX-101 in suicidal bipolar depression at the end of April highlights the difficulty of treating this intractable condition. The company is still moving fo

The US FDA’s user fee calendar for 2024 already features almost 60 new molecular entities and novel biologics, echoing the agency’s review workload at the beginning of 2023 – a position that contains

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F